277 related articles for article (PubMed ID: 2100875)
1. Levels of SC5b--9 complement complex in plasma and synovial fluid of patients with rheumatic disease.
Rus V; Malide D; Boloşiu HD; Parasca I; Duţu AL
Med Interne; 1990; 28(4):305-10. PubMed ID: 2100875
[TBL] [Abstract][Full Text] [Related]
2. [ELISA for detection of SC5b-9 levels in plasma and its clinical significance in SLE disease].
Kan D
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1993 Aug; 15(4):302-5. PubMed ID: 8168211
[TBL] [Abstract][Full Text] [Related]
3. [Terminal complement complex (TTC) levels in plasma and urine from glomerular diseases: enzyme-linked immunosorbent assay (ELISA) using monoclonal antibody against neoantigens of TCC].
Kusunoki Y
Hokkaido Igaku Zasshi; 1990 Jan; 65(1):74-85. PubMed ID: 2328949
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical determination of complement activation in joint tissues of patients with rheumatoid arthritis and osteoarthritis using neoantigen-specific monoclonal antibodies.
Kemp PA; Spragg JH; Brown JC; Morgan BP; Gunn CA; Taylor PW
J Clin Lab Immunol; 1992; 37(4):147-62. PubMed ID: 1285067
[TBL] [Abstract][Full Text] [Related]
5. Quantitative evaluation of the terminal C5b-9 complement complex by ELISA in human atherosclerotic arteries.
Niculescu F; Hugo F; Rus HG; Vlaicu R; Bhakdi S
Clin Exp Immunol; 1987 Aug; 69(2):477-83. PubMed ID: 3652536
[TBL] [Abstract][Full Text] [Related]
6. Terminal complement complex in plasma from patients with systemic lupus erythematosus and other glomerular diseases.
Horigome I; Seino J; Sudo K; Kinoshita Y; Saito T; Yoshinaga K
Clin Exp Immunol; 1987 Nov; 70(2):417-24. PubMed ID: 3427827
[TBL] [Abstract][Full Text] [Related]
7. Detection of the terminal fluid-phase complement complex, SC5b-9, in the plasma of patients with insulin-dependent (type I) diabetes mellitus. Relation to increased urinary albumin excretion and plasma von Willebrand factor.
Triolo G; Giardina E; Casiglia D; Scarantino G; Bompiani GD
Clin Exp Immunol; 1991 Apr; 84(1):53-8. PubMed ID: 2015712
[TBL] [Abstract][Full Text] [Related]
8. Radioimmunoassay of the attack complex of complement in serum from patients with systemic lupus erythematosus.
Falk RJ; Dalmasso AP; Kim Y; Lam S; Michael A
N Engl J Med; 1985 Jun; 312(25):1594-9. PubMed ID: 4000197
[TBL] [Abstract][Full Text] [Related]
9. [Complement activity in the serum and synovial fluid of various rheumatoid diseases].
Richter H; Thumb N; Gangl A; Zilcher H; Hornich R
Verh Dtsch Ges Rheumatol; 1972; 2():Suppl 2:106-10. PubMed ID: 4538173
[No Abstract] [Full Text] [Related]
10. Detection of activated terminal complement (C5b-9) in cerebrospinal fluid from patients with central nervous system involvement of primary Sjogren's syndrome or systemic lupus erythematosus.
Sanders ME; Alexander EL; Koski CL; Frank MM; Joiner KA
J Immunol; 1987 Apr; 138(7):2095-9. PubMed ID: 3559203
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.
Cheema GS; Roschke V; Hilbert DM; Stohl W
Arthritis Rheum; 2001 Jun; 44(6):1313-9. PubMed ID: 11407690
[TBL] [Abstract][Full Text] [Related]
12. Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis.
Brodeur JP; Ruddy S; Schwartz LB; Moxley G
Arthritis Rheum; 1991 Dec; 34(12):1531-7. PubMed ID: 1747138
[TBL] [Abstract][Full Text] [Related]
13. [Serum complement and synovial complement. Respective variations in rheumatic pathology].
Kourilsky O; Peltier AP; de Sèze S
Nouv Presse Med; 1972 Jun; 1(26):1769-76. PubMed ID: 4538278
[No Abstract] [Full Text] [Related]
14. Quantitation of complement proteins in rheumatic disease.
George D; Glass D
Clin Rheum Dis; 1983 Apr; 9(1):177-98. PubMed ID: 6603322
[TBL] [Abstract][Full Text] [Related]
15. Circulating complement breakdown products in patients with rheumatoid arthritis. Correlation between plasma C3d, circulating immune complexes, and clinical activity.
Nydegger UE; Zubler RH; Gabay R; Joliat G; Karagevrekis CH; Lambert PH; Miescher PA
J Clin Invest; 1977 May; 59(5):862-8. PubMed ID: 853126
[TBL] [Abstract][Full Text] [Related]
16. Measurement of terminal complement complexes in rheumatoid arthritis.
Morgan BP; Daniels RH; Williams BD
Clin Exp Immunol; 1988 Sep; 73(3):473-8. PubMed ID: 3208454
[TBL] [Abstract][Full Text] [Related]
17. [Study of the mechanism of the fall in complement levels in the synovial fluid in rheumatoid arthritis. II. Demonstration of an abnormal anti-complement property in rheumatoid synovial fluids].
Peltier AP; Vial MC; Leroy C; de Sèze S
Pathol Biol (Paris); 1970 Nov; 18(21):969-74. PubMed ID: 4099022
[No Abstract] [Full Text] [Related]
18. Prevalence of anti-3-nitrotyrosine antibodies in the joint synovial fluid of patients with rheumatoid arthritis, osteoarthritis and systemic lupus erythematosus.
Khan F; Siddiqui AA
Clin Chim Acta; 2006 Aug; 370(1-2):100-7. PubMed ID: 16513103
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous localization of the membrane attack complex in discoid and systemic lupus erythematosus.
Biesecker G; Lavin L; Ziskind M; Koffler D
N Engl J Med; 1982 Feb; 306(5):264-70. PubMed ID: 7054697
[TBL] [Abstract][Full Text] [Related]
20. [Importance of the determination of antibodies to n-DNA in systemic lupus erythematosus and other rheumatic diseases (comparative study of radioisotope and immunoenzyme technics)].
Riazantseva TA; Shakhanina KL; Aroian AA; Speranskiĭ AI
Ter Arkh; 1987; 59(8):86-91. PubMed ID: 3317973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
